Infectious Diseases in Critical Care Medicine

(ff) #1

  1. Stein DS, Nelson KE. Endocarditis due to nutritionally deficient streptococci: therapeutic dilemma.
    Rev Infect Dis 1987; 9:908–916.

  2. Gossling J. The occurrence and pathogenicity of the S milleri group. Rev Infect Dis 1988; 10:257.

  3. Murdoch DR, Reller LB. Antimicrobial susceptibility group B streptococci isolated from patients
    with invasive disease: 10-year prospective. Antimicrob Agents Chemother 2001; 45:3623–3624.

  4. Phares CR, Lynnfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease
    in the United States, 1999–2005. JAMA 2008; 299:2056–2065.

  5. Sambola A, Miro JM, Tornos MP, et al. Streptococcus agalactiae infective endocarditis: analysis of
    30 cases in review of the literature, 1962–1998. Clin Infect Dis 2002; 34:1576–1582.
    16a. Maki DG, Agger WA. Enterococcal bacteremia: Clinical features, the risk of endocarditis, and
    management. Medicine (Baltimore) 1988; 67:248–269.

  6. Brusch JL. Cardiac infections in the immunosuppressed patient. Infect Dis Clin NA 2001:15:613–638.

  7. West SK, Plantenga MS, Strausbaugh LJ, and Infectious Diseases Society of America Emerging
    Infectious Network. Culture-negative endocarditis and endocarditis caused by unusual pathogens
    including vancomycin-resistant enterococci: results of an emerging infections network survey.
    Infect Dis Clin Pract 2007; 15:316–319.

  8. Stevens MP, Edmond MB. Endocarditis due to vancomycin-resistant enterococci: case report and
    review of the literature. Clin Infect Dis 2005; 41:1134–1142.

  9. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy
    and management of complications: a statement for health care professionals From the Committee
    on Rheumatic Fever, Endocarditis and on Clinical Cardiology, Stroke and Cardiovascular Surgery
    and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of
    America. Circulation 2005; 111: e394–e434.

  10. Duval X, Papastamopoulos V, Longuet P, et al. Definite Streptococcus bovis endocarditis:
    characteristics in 20 patients. Clin Microbiol Infect 2001, 7:3—10.

  11. Moellering RC, Watson BK Kunz L. Endocarditis due to group D. streptococci. Comparison of
    disease caused by Streptococcus bovis with that caused by the enterococci Am J Med 1974; 57:
    239–250.

  12. Petti CA, Fowler VG. Staphylococcus aureus bacteremia and endocarditis. In: Durack DT, ed.
    Infective Endocarditis. Philadelphia: WB Saunders, 2002:413–435.

  13. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 2001; 345:1318–1330.

  14. Wiplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in U.S. hospitals:
    analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;
    39:309–317.

  15. Beekman S, Henderson DK. Infections caused by percutaneous intravascular devices. In: Mandel
    GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, Chapter 300. 6th ed.
    Philadelphia: Elseiver, Churchill Livingstone, 2005:3347–3362.

  16. Tompkins DC, Blackwell LJ, Hatcher VB, et al. Staphylococcus aureus proteins that bind to human
    endothelial cells. Infect Immun 1992; 60:9 65–969.

  17. Sheagren J. Staphylococcus aureus, the persistent pathogen. N Engl J Med 1984; 310:1368–1374.

  18. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis 1998; 26:1179–1181.

  19. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520–532.

  20. Chang F-Y, MacDonald BB, Peacock JE, et al. A prospective multicenter study of Staphylococcus
    aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of
    methicillin resistance. Medicine 2003; 82:322–332.

  21. Gotz F, Peters G. Colonization of medical devices by coagulase negative staphylococci. In:
    Waldvogel FA, Bisno Al, eds. Infections Associated with Indwelling Medical Devices. Washington
    D.C.: ASM press, 2000:55–88.

  22. Chu VH, Woods CW, Miro JM, et al. Emergence of coagulase- negative staphylococci as a cause a
    native valve endocarditis. Clin Infect Dis 2008; 46:232–242.

  23. Vandenesch F, Etienne J, Reverdy ME, et al. Endocarditis due to Staphylococcus lugdunensis:
    report of 11 cases and review. Clin Infect Dis 1993; 17:871–876.

  24. Doring J, Maier M, Mueller E. Virulence factors of pseudomonas aeruginosa. Antimicrob
    Chemother 1987; 39:136–148.

  25. Young F. Human immunity and Pseudomonas aeruginosa: in vitro interaction of bacteria,
    polymorphonuclear leukocytes and serum factors. J Infect Dis 1972; 26:257–263.

  26. Snyder N, Atterbury CE, Correia JP, et al. Increased occurrence of cirrhosis and bacterial
    endocarditis. Gastroenterol 1977; 33:1107–1112.

  27. Levine DP. Infectious endocarditis and intravenous drug abusers. In: Levine DP, Sobel JD, eds.
    Infections Intravenous Drug Abusers. New York: Oxford University press, 1991:251–285.


250 Brusch

Free download pdf